GANX

Gain Therapeutics, Inc.
CAPPED RATING

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Gain Therapeutics, Inc. (GANX) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D-). The rating has held at C- for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D-
Factor Score 1.1 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.7
EV / EBITDA -1.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -48.7%
Price Return 12M -55.4%
Catalyst Signal 0.00
Market Cap $48.4M
TTM Revenue N/A
Price / Sales N/A
ROE -268.3%

Historical Factor Score Progression

Held C- for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) D- (1.1) C- (2.0) D+ (1.5) C+ (2.6) C- (1.9)
2026-11-05 C+ (2.5) D (1.2) C- (2.1) C- (2.1) C+ (2.7) C- (2.1)
2026-10-29 C+ (2.5) D (1.2) C (2.2) C- (2.1) C+ (2.7) C- (2.1)
2026-10-22 C+ (2.5) D (1.2) C- (2.1) C- (2.1) C+ (2.6) C- (2.1)
2026-10-15 C+ (2.5) D (1.2) C- (2.1) C- (2.1) C+ (2.6) C- (2.1)
Page 1 of 4